58. End game vaccine for COVID-19, Marty Moore, Cofounder and CEO, Meissa Vaccines

episode

Biotech 2050 Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Oura Delays IPO Over Market Uncertainty 2 min · 29 Sep 2026 · WSJ Minute Briefing

Win Brooke's Bucks (9/29/26) 11 min · 29 Sep 2026 · Brooke and Jeffrey

Ex-Disney CEO BREAKS SILENCE on Bob Iger & The Truth About Disney | PBD Podcast #864 1h 59m · 29 Sep 2026 · PBD Podcast

A Relaxing Visit to Ek Balam 44 min · 29 Sep 2026 · Get Sleepy: stories for sleep

Ep. 2070 - Republican Campaign Ad Brutalizes Lazy White Men 51 min · 29 Sep 2026 · The Michael Knowles Show

The Dollar-Store Hour: Why Doing It Yourself is Costing You Millions 3 min · 29 Sep 2026 · The Level Up Podcast w/ Paul Alex

Report any issue

Source

Recorded12 May 2021

Publisherfeeds.soundcloud.com ↗

Handlerec:2866948

Show notes

Martin (Marty) is a cofounder and chief executive officer of Meissa Vaccines. Prior to cofounding Meissa, Marty was an Associate Professor at Emory University and director of the Emory Children’s Center for Childhood Infections and Vaccines (CCIV). He developed an RSV reverse genetics platform technology and novel strategies and methods for making vaccine candidates by synthetic biology. As applied to RSV vaccines, this technology was recognized as Emory University’s innovation of the year in 2013. Marty has more than 70 publications in virology, is co-inventor of 20 RSV-related technologies, and is a frequent national/international lecturer on RSV and vaccines.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in